Financial Results for the Fiscal Year ended March 31, 2016
[Japanese GAAP] (non-consolidated)
May 13, 2016
Name of Company
GreenPeptide Co., Ltd.
TSE Code4594
Representative(Title)
President & CEOContact(Title)
Director/CFO
Scheduled date of annual meeting of stockholders
Scheduled date of dividend payment commencement
Scheduled date of submission of securities report
Supplementary materials for financial statements
Briefing of financial results

Listed Market Mothers, TSEURL
http://www.green-peptide.com/(Name) Kenichi Nagai(Name) Teruhiko Sakai(TEL) +81-3-5840-7697: June 22, 2016:－: June 23, 2016
: None: Yes ( for analysts and institutional investors )(Millions of yen, rounded down to the nearest million)

1. Projected financial results for fiscal year 2015 (April 1, 2015 – March 31, 2016)(Percentages represent changes from the same period of previous year)(1) Results of Operation
Net sales

Operating income

Ordinary income

Net income

Million yen%

Million yen%

Million yen%

Million yen%

822
821

0.1
―

‐988
‐492―
―

‐992
‐413―
―

‐994
‐412―
―

Fiscal year ended March 31, 2016Fiscal year ended March 31, 2015

Return on
shareholders’equityNet income per Fully diluted netshareearnings per shareYenYen

Ratio of ordinary
income to total Operating margin
assets%%%Fiscal year ended March 31, 2016‐35.28―‐53.1‐48.4‐120.2
Fiscal year ended March 31, 2015‐20.60
―
‐68.0
‐50.9
‐59.9
(Reference) Equity in earnings of Fiscal 2015 ― Million yen
Fiscal 2014 ― Million yen(Notes) 1. As for class A preferred stocks (42,428 shares), upon exercise of the acquisition request with put options in considerationof ordinary stocks, we issued 42,428 shares of ordinary stock effective July 14, 2015 and acquired the mentioned class
A preferred stocks as treasury stocks. The treasury stocks were cancelled effective the same day. Then, the Company
conducted a 100-for-1 stock split of its ordinary stocks effective July 31, 2015. Net income per share has been calculated
as if a series of transaction for the stock split was conducted at the beginning of the previous fiscal year.
2. Fully diluted net earnings per share is not stated as net loss was recorded for this period although there are residual shares.

(2) Financial Positions
Total assets

Net assets

Million yen

As of March 31, 2016
As of March 31, 2015
(Reference)
Shareholders’ equity

Equity ratio

Net assets per share%

Million yen

Yen

2,877
2,720
94.6
85.53
1,227
1,024
83.4
30.74
As of March 31, 2016 2,720 Million yen As of March 31, 2015 1,024 Million yen(3) Cash Flows
Cash flows
from operating
activities

Cash flows
from investing
activities

Cash flows
from financing
activities

Cash and cash
equivalents at end ofperiod

Million yen

Million yen

Million yen

Million yen

‐908
‐447

‐32‐662,672
1,247

2,555823

Fiscal year ended March 31, 2016
Fiscal year ended March 31, 2015

2. Dividends
Ratio ofTotal dividends Payout
dividends to netpaid(annual)ratio
End of 1Q End of 2QEnd of 3Q Year-end Annual
assetsAnnual Dividends per share

Fiscal year ended March 31, 2015
Fiscal year ended March 31, 2016
Fiscal year ending March 31,2017 (Forecast)

Yen

Yen

Yen

Yen

Yen

Million yen

%%

――

0.00
0.00

――

0.00
0.00

0.00
0.00

―――――――

0.00

―

0.00

0.00

―

3. Projected financial results for fiscal year ending March 31, 2017 (April 1, 2016 – March 31, 2017)(Percentages represent changes from the same period of previous year)
Net income
Operating income Ordinary income
Net income
per share

Net sales
Million yen

Full year406% Million yen‐50.5‐1,306―1―% Million yen% Million yen%Yen―――‐41.14‐1,306‐1,308

[Notes](1) Changes in significant accounting policies, changes in accounting estimates and restatement
1) Changes in accounting policies due to revisions of accounting standards, etc.

: None2) Changes in accounting policies due to other reasons than above 1): None3) Changes in accounting estimates: None4) Restatements: None(2) Number of shares outstanding (common stock)1) Number of shares outstanding at the end As of March 31,
of fiscal term (including treasury stocks) 2016
2) Number of treasury stocks at the end of As of March 31,
2016
fiscal term3) Average number of shares during the Year ended
March 31, 2016
fiscal term

31,807,700

shares

As of March 31,
2015

25,307,700

shares―shares

As of March 31,
2015―

shares28,184,750

sharesYear ended
March 31, 2015

20,024,100

shares(Notes) Due to a 100-for-1 stock split which was conducted with an effective date of July 31, 2015, the number of shares iscalculated as if such stock split was implemented at the beginning of the previous fiscal year.

* Disclosure regarding the implementation of audit procedures.
These financial results are outside the scope of audit procedures under the Financial Instruments and Exchange Act. At thetime of disclosure of these financial results, audit procedures for the financial statements under the Financial Instruments
and Exchange Act have not been completed.

* Explanations regarding appropriate use of forecasts and projections of financial results, and other specific notes.
All forecasts and projections contained in this presentation are based on the information currently available to themanagement and they are not intended to represent our promise to attain them as a goal. Furthermore, due to various reasons,actual results may differ substantially.

―2―

Financial statements(1) Balance sheets(Thousands of yen)
As of March 31, 2015
AssetsCurrent assets
Cash and deposits
Accounts receivable - trade
Merchandise and finished products
Work in process
Raw materials and supplies
Advance payments - trade
Advance payments - otherAccounts receivable - otherConsumption taxes receivable
Other

As of March 31, 2016

823,737
79,5994,573
16,770127,157
12,17957,126
10,475
12,17012,1892,555,458
106,749
12,66623,573
8,061
63,031
9,338
2,074
10,404

1,155,979

2,791,358

Property, plant and equipment
Facilities attached to buildings, net
Machinery and equipment, net
Tools, furniture and fixtures, net

14,539979
29,735

12,424737
35,359Total property, plant and equipment

Total current assets
Non-current assets

45,25548,521Intangible assets
Software
Software in progress

2,157
-

1,903
9,352

Total intangible assets

2,157

11,256

Investments and other assets
Guarantee deposits
Long-term prepaid expenses

24,073-24,0732,041

24,073

26,115

Total investments and other assets
Total non-current assets
Total assets―3―71,48685,893

1,227,465

2,877,251

(Thousands of yen)
As of March 31, 2015

As of March 31, 2016

Liabilities
Current liabilities
Accounts payable - trade
Accounts payable - otherAccrued expenses
Income taxes payable
Advances received
Deposits received

57,92045,156
2,264
4,531
66,8502,186

66,30829,922
2,988
10,487
16,361
2,828

Total current liabilities

178,910

128,897

Non-current liabilities
Provision for retirement benefits
Deferred tax liabilities
Asset retirement obligations

14,9682,076
7,383

18,5201,715
7,455

Total non-current liabilities

24,427

27,690Total liabilities

203,337

156,588

Capital stock
Capital surplus
Legal capital surplus

642,585

1,988,085

626,170

1,971,670

Total capital surpluses

626,170

1,971,670

Retained earnings
Other retained earnings
Retained earnings brought forward

Net assets
Shareholders' equity‐244,627‐1,239,092

Total retained earnings‐244,627‐1,239,092

Total shareholders' equity

1,024,127

2,720,663

1,024,127

2,720,663

1,227,465

2,877,251

Total net assets
Total liabilities and net assets―4―(2) Statements of operations(Thousands of yen)
Fiscal year ended
March 31, 2015
Net sales
Revenue from research and development
Net sales of finished products
Net sales of goodsFiscal year ended
March 31, 2016

815,510
1,730
4,385

815,750
2,345
4,460

821,625

822,556

763,797

768,438

3,375
―

2,923
8,311

Total

3,375

11,235Ending finished products

2,923

10,356

Cost of finished products soldCost of goods soldBeginning goods

451

879

1,020

1,650

Cost of purchased goods

3,000

3,000

Total

4,020

4,650

Ending goods

1,650

2,310

Total net sales
Cost of sales
Research and development costs
Cost of finished products soldBeginning finished products
Cost of products manufactured

Cost of goods soldTotal cost of sales

2,370

2,340

766,619

771,657

Gross profit

55,00650,898Selling, general and administrative expenses

547,192

1,039,649

Operating loss

‐492,186‐988,750

129
83,308
780
1,870
134

274
13,788――167

86,222

14,230Interest expenses
Foreign exchange losses
Loss on cancellation by clinical trial sites
Stock issuance expenses

0
1,041
1,870
4,623

16
―
―
18,441

Total non-operating expenses

7,536

18,458‐413,501‐992,977

5,100

―

5,100

―

Non-operating income
Interest income
Subsidy income
Income from assignment of reagents for research
Income from cancellation by clinical trial sites
Other
Total non-operating income
Non-operating expenses

Ordinary loss
Extraordinary income
Gain on reversal of subscription rights to shares
Total extraordinary income―5―(Thousands of yen)
Fiscal year ended
March 31, 2015

Fiscal year ended
March 31, 2016

Extraordinary losses
Loss on retirement of non-current assets

31―

Total extraordinary losses

31―‐408,432
1,927
2,076

‐992,977
1,847
‐360

Loss before income taxes
Income taxes - current
Income taxes - deferred
Total income taxes
Net Loss―6―

4,003

1,486

‐412,435‐994,464

(3) Statements of cash flows(Thousands of yen)
Fiscal year ended
March 31, 2015
Cash flows from operating activities
Loss before income taxes

Fiscal year ended
March 31, 2016

‐408,432‐992,977

Depreciation

8,802

19,304

Increase (decrease) in provision for retirement benefits

2,179

3,552

‐129

‐274

Subsidy income‐83,308‐13,788

Gain on reversal of subscription rights to shares‐5,100－31

Interest and dividend income

Loss on retirement of property, plant and equipment
Decrease (increase) in accounts receivable - trade33,142－‐27,150

Decrease (increase) in inventories‐13,417112,261

Increase (decrease) in accounts payable - trade‐42,388

8,388

Increase (decrease) in advances received‐11,191‐50,488

Other, net‐8,896

20,240Subtotal‐528,707‐920,932

Interest and dividend income received
Subsidy income recieved

129
83,308274
13,788

Income taxes paid

‐1,926‐1,841‐447,197‐908,711

Net cash provided by (used in) operating activities
Cash flows from investing activities
Purchase of property, plant and equipment‐40,552‐22,523

Purchase of intangible assets‐2,311‐9,602

Payments for guarantee deposits‐24,073－

Proceeds from collection of guarantee deposits

2,725

－

Payments for asset retirement obligations‐2,642－

Net cash provided by (used in) investing activities
Cash flows from financing activities
Proceeds from issuance of common stock‐66,854‐32,125

1,247,716

2,672,558

1,247,716

2,672,558―－
1,731,721

Net cash provided by (used in) financing activities
Effect of exchange rate change on cash and cash equivalents
Net increase (decrease) in cash and cash equivalents

733,664

Cash and cash equivalents at beginning of period

90,073

823,737

Cash and cash equivalents at end of period

823,737

2,555,458―7―